It’s been a crucial week for Celgene Corporation (NASDAQ:CELG); here’s what analysts have to say.

July 27, 2018 - By Lisa Delgado

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.79 in 2018 Q1. Its down 0.04, from 0.83 in 2017Q4. It worsened, as 120 investors sold Celgene Corporation shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported.
Northwestern Mutual Wealth Mgmt Co owns 0.03% invested in Celgene Corporation (NASDAQ:CELG) for 50,809 shares. Cape Cod Five Cents Bancorp holds 2,485 shares or 0.03% of its portfolio. Bluemountain Capital Management Llc holds 135,856 shares or 0.28% of its portfolio. Azimuth Capital Mgmt Llc holds 0.35% or 53,329 shares in its portfolio. Malaga Cove Capital Ltd, a California-based fund reported 5,545 shares. State Of Tennessee Treasury Department holds 0.22% or 472,433 shares in its portfolio. Strs Ohio holds 509,968 shares or 0.2% of its portfolio. Twin Capital holds 0.1% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 22,460 shares. Altfest L J & Company reported 5,541 shares or 0.21% of all its holdings. Mairs And Power has 0% invested in Celgene Corporation (NASDAQ:CELG) for 3,030 shares. Money Management Lc holds 15,900 shares or 0.89% of its portfolio. Dimensional Fund Advisors Ltd Partnership owns 1.84M shares. Honeywell Interest has invested 0.83% in Celgene Corporation (NASDAQ:CELG). Shell Asset Mgmt Com holds 72,758 shares. Of Vermont invested in 0.59% or 70,171 shares.

Since February 8, 2018, it had 2 insider purchases, and 5 sales for $5.91 million activity. 18,500 shares valued at $1.77M were sold by KAPLAN GILLA on Thursday, February 15. Alles Mark J also bought $299,594 worth of Celgene Corporation (NASDAQ:CELG) shares. CASEY MICHAEL D also sold $1.02 million worth of Celgene Corporation (NASDAQ:CELG) on Thursday, June 7. The insider MARIO ERNEST sold $1.26 million.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 18 analysts covering Celgene (NASDAQ:CELG), 13 have Buy rating, 0 Sell and 5 Hold. Therefore 72% are positive. Celgene has $16300 highest and $90 lowest target. $119.17’s average target is 34.95% above currents $88.31 stock price. Celgene had 22 analyst reports since February 5, 2018 according to SRatingsIntel. William Blair maintained Celgene Corporation (NASDAQ:CELG) on Wednesday, February 28 with “Buy” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, July 13. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Stifel Nicolaus on Wednesday, February 28. The firm has “Overweight” rating given on Wednesday, March 21 by JP Morgan. The firm has “Buy” rating given on Tuesday, February 13 by Barclays Capital. On Monday, June 18 the stock rating was upgraded by Standpoint Research to “Buy”. Oppenheimer maintained the stock with “Buy” rating in Friday, May 25 report. The firm has “Equal-Weight” rating given on Friday, April 13 by Morgan Stanley. Credit Suisse maintained it with “Outperform” rating and $129 target in Wednesday, February 28 report. The stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by SunTrust on Wednesday, February 28. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

13/07/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $90 New Target: $91 Maintain
18/06/2018 Broker: Standpoint Research Old Rating: Hold New Rating: Buy Upgrade
31/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $112.0000 Maintain
25/05/2018 Broker: Oppenheimer Rating: Buy New Target: $163.0000 Maintain
23/05/2018 Broker: Argus Research Old Rating: Buy New Rating: Hold Downgrade
23/05/2018 Broker: Bernstein Rating: Buy Upgrade
07/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $93 New Target: $90 Maintain
07/05/2018 Broker: Leerink Swann Rating: Buy New Target: $115.0000 Maintain
07/05/2018 Broker: RBC Capital Markets Old Rating: Top Pick New Rating: Outperform Old Target: $120 New Target: $118 Downgrade
30/04/2018 Broker: Evercore Rating: Buy

The stock increased 0.73% or $0.64 during the last trading session, reaching $88.31. About 7.28 million shares traded or 6.04% up from the average. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since July 27, 2017 and is downtrending. It has underperformed by 45.22% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $64.01 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 24.67 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: which released: “What’s Next for Pfizer Stock After Being Called Out by President Trump” on July 24, 2018, also with their article: “Celgene and Acceleron Pharma Win Again in Late-Stage Trial” published on July 10, 2018, published: “Company Profile: Surface Oncology” on July 22, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: and their article: “Celgene: Fears Are Overplayed” published on July 10, 2018 as well as‘s news article titled: “Are CEOs Really Worth What They’re Paid?” with publication date: July 19, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.